



24390-01-26-06.txt
SEQUENCE LISTING

<110> Yeda Research and Development Company Ltd.

<120> ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE

<130> 1276302

<140> 09/647,457

<141> 2000-09-29

<150> PCT/IL99/00190

<151> 1999-09-29

<150> 123925

<151> 1998-04-02

<160> 15

<170> PatentIn version 3.3

<210> 1

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> being the immunologically active epitope

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa(1) is S or absent

<220>

<221> MISC_FEATURE

<222> (1)..(11)

<223> provided that when xaa(11) is absent, xaa(1) through xaa(10), inclusive, are absent, and when Xaa(11) is D , Xaa(10) is A or absent

<220>

<221> MISC_FEATURE

<222> (1)..(10)

<223> when Xaa(10) is absent, Xaa(1) through Xaa(9), inclusive, are absent, and when Xaa(10) is A, Xaa(9) is I or absent

<220>

<221> MISC_FEATURE

<222> (1)..(9)

<223> when Xaa(9) is absent, Xaa(1) through Xaa(8), inclusive, are absent, and when Xaa(9) is I, Xaa(8) is F or absent

<220>

<221> MISC_FEATURE

<222> (1)..(8)

<223> when Xaa(8) is absent, Xaa(1) through Xaa(7), inclusive, are absent, and when Xaa(8) is F, Xaa(1) through Xaa(7) are, respectively, S, G, E, T, E, D, and T

<220>

<221> MISC_FEATURE

<222> (2)..(2)
<223> Xaa(2) is G or absent

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa(3) is E or absent

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa(4) is T or absent

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa(5) is E or absent

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa(6) is D or absent

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa(7) is T or absent

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa(8) is F or absent

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa(9) is I or absent

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa(10) is A or absent

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Xaa(19) is C, G, P

<220>
<221> MISC_FEATURE
<222> (25)..(25)
<223> Xaa(25) is A, P

<220>
<221> MISC_FEATURE
<222> (25)..(28)
<223> Xaa(28) is R or absent, provided that Xaa(25) and Xaa(26) are taken together to form a sequence selected from the group consisting of AP and PA

<220>
<221> MISC_FEATURE
<222> (26)..(26)

<223> Xaa(26) is P, A

<400> 1

Xaa Leu Val Val Gly Leu
1 5 10 15

Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Xaa Cys Xaa
20 25

<210> 2

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> being the immunologically active epitope

<400> 2

Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
1 5 10 15

Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
20 25

<210> 3

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated
levels in body fluids of schizophrenic patients.

<400> 3

Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
1 5 10 15

<210> 4

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated
levels in body fluids of schizophrenic patients.

<400> 4

Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
1 5 10 15

Ala Pro Cys Arg
20

<210> 5
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 5

Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala
1 5 10 15

Pro Cys Arg

<210> 6
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 6

Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
1 5 10 15

Cys Arg

<210> 7
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 7

Leu Val Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
1 5 10 15

Arg

<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 8

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
1 5 10 15

Arg

<210> 9
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 9

Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
1 5 10 15

Arg

<210> 10
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 10

Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
1 5 10 15

Cys Thr Gly Gln
20

<210> 11
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 11

val val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
1 5 10 15

<210> 12

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 12

Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
1 5 10

<210> 13

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 13

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
1 5 10 15

<210> 14

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 14

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
1 5 10 15

<210> 15

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 15

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
1 5 10 15